Skip to main content

roche-logo

The team at Roche’s Basel-based underdog R&D group pRED has something to cheer about today. The FDA has designated their autism drug RG7314 (balovaptan) as a “breakthrough” therapy worthy of VIP treatment at the agency.

{iframe}https://endpts.com/roche-scores-an-unusual-breakthrough-at-the-fda-for-an-autism-drug/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.